Bruce E Strober (Bruce Strober, B Strober, B E Strober)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 50

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

The British journal of dermatology

Dermatology and therapy

Journal of psoriasis and psoriatic arthritis

Yale University School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Yale University School of Medicine Jan 01 2020

United States

Clinical Professor :: Dermatology

Publications

Bruce E Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda J Gooderham, Martin Alan Menter, Robert Strohal, Michael M Chen, Tianshuang Wu, Tianyu Zhan, Huzefa Photowala, April W Armstrong
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Bruce E Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda J Gooderham, Martin Alan Menter, Robert Strohal, Michael M Chen, Tianshuang Wu, Tianyu Zhan, Huzefa Photowala, April W Armstrong
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (5) (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Bruce E Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata M Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, George M Martin, Nicole N Rawnsley, Earl L Goehring, Abby A Jacobson
Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology and therapy 14 (5) (2024)
Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Bruce E Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda J Gooderham, Martin Alan Menter, Robert Strohal, Michael M Chen, Tianshuang Wu, Tianyu Zhan, Huzefa Photowala, April W Armstrong
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (5) (2024)
Bruce E Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata M Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Bruce E Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata M Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Bruce E Strober, Laura C Coates, Mark G Lebwohl, Atul Deodhar, Evan Leibowitz, Katelyn Rowland, Alexa P Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D Chakravarty, Daphne Chan, May Shawi, Ya-Wen Yang, Diamant Thaҫi, Proton Rahman
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug safety (2023)
A Armstrong, Kilian Eyerich, Curdin Conrad, Y Zhu, Y-W Yang, M Miller, Y You, Y K Shen, P Foley, Christopher Ernest Maitland Griffiths, Bruce E Strober
Immunogenicity and Pharmacokinetics of Guselkumab Among Patients with Moderate-to-Severe Psoriasis in VOYAGE-1 and VOYAGE-2. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lars E Kristensen, Bruce E Strober, Denis Poddubnyy, Ying Ying Leung, Hyejin Jo, Kenneth Kwok, Ivana Vranic, Dona L Fleishaker, Lara Fallon, Arne Yndestad, Dafna D Gladman
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Therapeutic advances in musculoskeletal disease 15 (2023)
Diamant Thaҫi, Ronald B Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce E Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B Kimball
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. The British journal of dermatology 188 (1) (2023)
Andrew Blauvelt, George C Gondo, Stacie J Bell, Cristina Echeverría, Marcus Schmitt-Egenolf, Lone Skov, Peter Cornelis Maria van de Kerkhof, Leah McCormick Howard, Bruce E Strober
Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities. Journal of psoriasis and psoriatic arthritis 8 (3) (2023)
Jonathan Ian Silverberg, Lars Einar French, Richard B Warren, Bruce E Strober, Kim Kjøller, Morten O A Sommer, Philippe Andres, Jakob Felding, Anne Weiss, Deniz Tutkunkardas, Tine Skak-Nielsen, Emma Guttman-Yassky
Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal of the European Academy of Dermatology and Venereology : JEADV 37 (4) (2023)
Georgios Kokolakis, Richard Bruce Warren, Bruce E Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda J Gooderham, Andreas Körber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology 188 (3) (2023)
Bruce E Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Richard Bruce Warren, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle F Paul
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. The British journal of dermatology (2023)
Jonathan Ian Silverberg, Lars Einar French, Richard B Warren, Bruce E Strober, Kim Kjøller, Morten O A Sommer, Philippe Andres, Jakob Felding, Anne Weiss, Deniz Tutkunkardas, Tine Skak-Nielsen, Emma Guttman-Yassky
Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal of the European Academy of Dermatology and Venereology : JEADV 37 (4) (2023)
Diamant Thaҫi, Ronald B Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce E Strober, Veerle Vanvoorden, Maggie Wang, Cynthia Madden, Dirk de Cuyper, Alexa B Kimball
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. The British journal of dermatology 188 (1) (2023)
Georgios Kokolakis, Richard Bruce Warren, Bruce E Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda J Gooderham, Andreas Körber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology 188 (3) (2023)
K Reich, Jonathan Ian Silverberg, Kim A Papp, Mette Deleuran, N Katoh, Bruce E Strober, Lisa A Beck, M de Bruin-Weller, T Werfel, F Zhang, P Biswas, M D DiBonaventura, G Chan, S Johnson, S A Farooqui, U Kerkmann, C Clibborn
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
K Reich, Jonathan Ian Silverberg, Kim A Papp, Mette Deleuran, N Katoh, Bruce E Strober, Lisa A Beck, M de Bruin-Weller, T Werfel, F Zhang, P Biswas, M D DiBonaventura, G Chan, S A Farooqui, U Kerkmann, C Clibborn
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Bruce E Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Richard Bruce Warren, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle F Paul
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. The British journal of dermatology (2023)
Lars E Kristensen, Bruce E Strober, Denis Poddubnyy, Ying Ying Leung, Hyejin Jo, Kenneth Kwok, Ivana Vranic, Dona L Fleishaker, Lara Fallon, Arne Yndestad, Dafna D Gladman
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Therapeutic advances in musculoskeletal disease 15 (2023)
Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, Yukari Okubo, Michael M Witte, Claudia Rodriguez Capriles, Angelina Sontag, Vipin Arora, Olawale Osuntokun, Bruce E Strober
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). The British journal of dermatology 187 (6) (2022)
Jonathan Ian Silverberg, Lars Einar French, R B Warren, Bruce E Strober, K Kjøller, M O A Sommer, P Andres, J Felding, A Weiss, Deniz Tutkunkardas, Tine Skak-Nielsen, E Guttman
Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Bruce E Strober, Dhaval Patil, Robert R McLean, Melissa Moore-Clingenpeel, Ning Guo, Eugenia Levi, Mark Lebwohl
Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting. Dermatology and therapy 12 (6) (2022)
Bruce E Strober, Dhaval Patil, Robert R McLean, Melissa Moore-Clingenpeel, Ning Guo, Eugenia Levi, Mark Lebwohl
Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting. The Journal of dermatological treatment (2022)
Kristian Reich, K B Gordon, Bruce E Strober, R G Langley, M Miller, Y-W Yang, Y-K Shen, Y You, Y Zhu, P Foley, Andrew Blauvelt
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (12) (2022)
Georgios Kokolakis, Richard Bruce Warren, Bruce E Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda J Gooderham, Andreas Körber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology (2022)
R B Warren, Bruce E Strober, Jonathan Ian Silverberg, E Guttman, P Andres, J Felding, Deniz Tutkunkardas, K Kjøller, M O A Sommer, Lars Einar French
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Melinda J Gooderham, Andreas Pinter, L K Ferris, R B Warren, Tianyu Zhan, J Zeng, A M Soliman, C Kaufmann, B Kaplan, H Photowala, Bruce E Strober
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (6) (2022)
Samantha Goldburg, Rebecca Chen, Wayne Langholff, Kimberly Parnell Lafferty, Melinda Gooderham, Elke Mgj de Jong, Bruce E Strober
Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal of psoriasis and psoriatic arthritis 7 (3) (2022)
M Lebwohl, R A Medeiros, R H Mackey, L R Harrold, W C Valdecantos, M Flack, A K Golembesky, N Kotowsky, Bruce E Strober
The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas' Psoriasis Registry. Journal of psoriasis and psoriatic arthritis 7 (2) (2022)
Mark G Lebwohl, Rose Anne Medeiros, Rachel H Mackey, Wendell C Valdecantos, Kimberly G Brodovicz, Apinya Lertratanakul, Bruce E Strober
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry. Journal of psoriasis and psoriatic arthritis 8 (2) (2022)
Jonathan Ian Silverberg, Lars Einar French, Richard B Warren, Bruce E Strober, Kim Kjøller, Morten O A Sommer, Philippe Andres, Jakob Felding, Anne Weiss, Deniz Tutkunkardas, Tine Skak-Nielsen, Emma Guttman-Yassky
Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Kristian Reich, Kenneth B Gordon, Bruce E Strober, April W Armstrong, Megan Miller, Y K Shen, Y You, C Han, Y W Yang, Peter Foley, Christopher Ernest Maitland Griffiths
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. The British journal of dermatology (2021)
Abby S Van Voorhees, L Stein Gold, M Lebwohl, Bruce E Strober, Howard Sofen, Kim A Papp, J Bagel, Z Zhang, M Paris, Y Wang
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. The British journal of dermatology 185 (4) (2021)
Bruce E Strober, Joyce Leman, Maja Mockenhaupt, Juliana Nakano de Melo, Ahmed Nassar, Vimal H Prajapati, Paolo Romanelli, Julien Seneschal, Athanasios Tsianakas, Lee Yoong Wei, Masahito Yasuda, Ning Yu, Ana C Hernandez Daly, Yukari Okubo
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line. Dermatology and therapy 12 (2) (2021)
Bruce E Strober, Nirali Kotowsky, Rose Medeiros, Rachel H Mackey, Leslie R Harrold, Wendell C Valdecantos, Mary Flack, Amanda K Golembesky, Mark Lebwohl
Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. Dermatology and therapy 11 (2) (2021)
April W Armstrong, Andrew Blauvelt, J J Crowley, K B Gordon, G G Krueger, J G Krueger, J M Sobell, Bruce E Strober, B Srivastava, A Menter
Defining drug-free remission of skin disease in patients with plaque psoriasis. The British journal of dermatology 182 (6) (2020)
Bruce E Strober, A Menter, C Leonardi, K Gordon, J Lambert, Lluis L Puig, H Photowala, M Longcore, T Zhan, P Foley
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (12) (2020)
C Leonardi, Kim A Papp, Bruce E Strober, D Thaçi, R B Warren, S Tyring, D Arikan, M Karunaratne, W C Valdecantos
Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. The British journal of dermatology 180 (1) (2018)
Bruce E Strober, A B Gottlieb, P C M van de Kerkhof, Lluis L Puig, H Bachelez, E Chouela, S Imafuku, D Thaçi, H Tan, H Valdez, P Gupta, M Kaur, V Frajzyngier, R Wolk
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. The British journal of dermatology 180 (1) (2018)
Bruce E Strober, J Crowley, R G Langley, K Gordon, A Menter, C Leonardi, D Arikan, W C Valdecantos
Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. Journal of the European Academy of Dermatology and Venereology : JEADV 32 (12) (2018)
R B Warren, Kristian Reich, R G Langley, Bruce E Strober, D Gladman, A Deodhar, T Bachhuber, W Bao, E Altemeyer, S Hussain, J Safi
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. The British journal of dermatology 179 (5) (2018)
Bruce E Strober, R G B Langley, A Menter, M Magid, B Porter, T Fox, J Safi, C Papavassilis
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis. The British journal of dermatology 178 (2) (2017)

Bruce E Strober.css-eqlu8i{font-size:small;padding-left:4px;} (Bruce Strober, B Strober, B E Strober)

Publication Activity (10 Years)

Top Topics

Top Venues

Bruce E Strober (Bruce Strober, B Strober, B E Strober)